ASX BRIEFS
Welcome to 'ASX BRIEFS,' the definitive podcast for enthusiasts, investors, and professionals keen on staying ahead of the curve in the Australian Stock Exchange (ASX). Hosted by Andrew Musgrave, 'ASX BRIEFS' delves deep into the heart of Australia's financial markets, bringing you insightful conversations with the minds shaping the future of investing down under. Each episode, join Andrew as he interviews a diverse lineup of fund managers, executives, and industry insiders, offering you a unique blend of expert analysis, strategic insights, and the latest trends affecting the ASX. Whether you're a seasoned investor or just starting out, 'ASX BRIEFS' is your go-to source for comprehensive updates and thought-provoking discussions designed to inform, inspire, and empower your investment journey. Tune in to 'ASX BRIEFS' and take the pulse of Australia's financial markets right at your fingertips.
ASX BRIEFS
CYBAN - Revolutionizing Brain Injury Care: Cyban's Dr. Mary Beth Brinson on the Breakthrough Brain Pulse Monitor and Its Path to FDA Approval
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
How does a non-invasive device revolutionize brain injury management? Join us on ASX Briefs as we welcome Dr. Mary Beth Brinson from Cyban, the medtech trailblazer behind the innovative Brain Pulse Monitor. Discover how this cutting-edge technology provides continuous brain oxygen monitoring from the trauma site all the way to hospital discharge, giving clinicians real-time data to make quick, life-saving decisions. Dr. Brinson breaks down the device's use of optical sensors and machine learning algorithms, showcasing how it dramatically outperforms traditional, often subjective monitoring methods.
Dr. Brinson also shares compelling insights from recent clinical trials conducted at top institutions like Victoria and Duke University. Learn how these trials have validated the Brain Pulse Monitor’s accuracy and safety, paving the way for imminent FDA approval. This episode offers an inside look at the future of brain injury care and how Cyban's technology could transform patient outcomes and the healthcare system. Tune in and get an exclusive preview of this medical breakthrough that promises to change the game for brain injury management.
Welcome to ASX Briefs . Today , we're joined by Dr Mary Beth Brinson from Cyban , a pioneering medtech company dedicated to transforming the management of brain injuries . Cyban has developed a groundbreaking brain pulse monitor that offers non-invasive , continuous brain oxygen monitoring from the site of trauma to hospital discharge . Today we'll delve into how this technology works , its benefits and the impact it's expected to have on both patients and the healthcare system . Thanks for joining us today , Mary Beth , and welcome to the podcast .
Mary Beth BrinsonThank you , Andrew , very pleased to be here .
Andrew MusgraveNow , with Cyban being an unlisted company , can you just begin by giving the audience an overview of Cyban and the Brain Pulse Monitor ?
Mary Beth BrinsonSure , Cyban's a novel medical device company that's dedicated to changing the standard of care and brain monitoring by improving how patients with a brain injury or at risk of a brain injury are monitored , which gives the clinician the earliest possible indication that the patient is declining , which will allow earlier intervention and ensure better outcomes for the patient . Our patented brain pulse monitor is non-invasive , bilateral and provides continuous information about blood flow in the brain . It extracts a proprietary waveform that is embedded with rich physiological data that can be decoded using a machine learning algorithm , which can provide additional information about the status of the brain to the clinician .
Andrew MusgraveAnd can you just explain how it marks a significant advancement in the treatment of brain injuries ?
Mary Beth BrinsonSure . About 85% of patients today that have had a head injury are monitored by a subjective or physical assessment of their condition . It's the physical assessment that you see in all movies in the ICU , where somebody comes in and checks them . This type of monitoring occurs on a fixed time schedule and if a patient declines it's often not seen until the next monitoring period . Brain tissue dies in less than two minutes without oxygen . So this type of monitoring is definitely a lagging indicator when a patient condition deteriorates and it's often not caught immediately . This can lead to significant complications and poor outcomes , and with the Cyban brain pulse monitor , the clinician gets notified immediately . It's a change in the blood flow to the brain allowing therapeutic interactions to occur very fast .
Andrew MusgraveCan you also discuss the specific technological innovations that enable the device to provide continuous and reliable monitoring without the need for invasive surgery ?
Mary Beth BrinsonSure . So our sensor is an optical sensor and the geometry has been optimized to capture the photons that are reflected from the venules or the blood vessels on the surface of the brain . We actually also show the brain pulse , the brain wave , on the screen , in addition to the oxygen values , which allows the clinician to be confident that the measure that they're seeing is actually a brain blood flow output . In the past there have been devices that display a number and the number has been erroneous and there was no way to confirm that it actually wasn't a skin measure , for instance , or a muscle movement measure . So , in addition to the patented sensor , the waveform that's extracted is also proprietary and we can decode that with machine learning algorithms , which provides an additional set of information back to the clinician .
Andrew MusgraveOkay , and you've also just recently undertaken some clinical trials across multiple locations , including Victoria and overseas . Can you share just some of the insights into these trials and update us on the progress towards FDA approval ?
Mary Beth BrinsonCertainly . We have and are running several trials and I'll give you some highlights . So for the product that is pending FDA approval , the FDA required a specific type of trial and that was run at Duke University and it's a validation of the product's ability to accurately measure blood oxygen levels . These are very specific trials and there are very few centers in the world that do this type of study . We're pleased to note that we exceeded the minimum efficacy requirement that the FDA told us that we had to achieve . The FDA submission was made in February . We expect approval in the middle of July .
Mary Beth BrinsonSo that's one study . We have an exploratory study that's run here in Victoria and has produced so much information about the waveform and different applications for the device . In addition , we now have data from over 200 patients from that study and we can report that we've had no adverse or severe adverse events , which is a huge achievement . So the device is very , very , very safe to use . We're also currently finishing a study specifically looking at strokes here in Victoria . This trial produced a new patent and we're just submitting the study for presentation and , as a teaser , we have recorded distinct and repeatable waveforms during a stroke that can provide prognostic information about strokes . We're also running a study in the United States at Cleveland Clinic looking at intracranial pressure with our device . I look to finish that up in the next six months .
Andrew MusgraveOkay , and with the brain pulse monitor itself and how it assists patients in practical terms , can you just provide some examples how early intervention facilitated by the device can change patient outcomes ?
Mary Beth BrinsonCertainly Look . It's well accepted in medicine that earlier identifications of problems is better . It saves lives and money , and that's just a general principle . In patients that have had a head injury or some complex cardiovascular or spinal surgery , for instance , this principle also holds true . Late identification of poor or low blood-brain flow is catastrophic for the patient and costly for the healthcare systems trying to manage that bad outcome . So by alerting the care team immediately to changes in the patient's brain blood flow status , the team has many options , including medication sending for an immediate picture or image of the brain to see what's going on . They can do surgery . They can change position of the patient . So there are options if they know early on that this is happening , before permanent damage has occurred . These are clinical decisions and they're made by the physicians . We help the clinicians and the physicians know that there's a problem early and that they can then go into their clinical protocols and execute options that save the patient's life and improve the outcome .
Andrew MusgraveNow , this technology not only benefits patients , but also promises significant advantages for healthcare systems . Can you just elaborate on how it helps reduce hospital costs and resource use ?
Mary Beth BrinsonSure , bad or unexpected outcomes cost money for healthcare systems, its really that simple . So if a patient has a significant brain blood flow issue it will cost the hospital additional procedures, additional staff time, and the healthcare system overall particularly for outcomes that produce lifetime care burdens cost the healthcare system like Australia and remaining life of that patient, so you pay significantly more money for these poor outcomes at the hospital level and at the general health care system level . So if the problem can be discovered early and actions can be taken to avoid permanent or significant damage , the health care costs come down . Additionally , with the physical alarm and a continuous brain monitor , it may be likely that the hospital staff can change their care routines and possibly care for and monitor more patients than if they're having to do a physical exam .
Andrew MusgraveNow you've received significant support from investors and the Victorian government . How important has this support been and what role do these partnerships play in your plans moving forward ?
Mary Beth BrinsonWe have had tremendous support from the Victorian government through grants and entities like Breakthrough Victoria , and our investors have been with us for this whole ride for over four years . Medical device startup companies need lots of support and they need it at discrete time periods , so like a small baby , really , where you need regular support . With the support that we have received , we've been able to grow stronger . We can consistently achieve the next milestones that set the company up to make a real run at a major market like the United States , and we simply could not have done it without our investors and the support of the Victorian government . We're grateful for their ongoing support as we make these first commercial steps .
Andrew MusgraveAnd I think , just to finish up , what are some of the key milestones you're looking to achieve in the next 12 to 24 months ?
Mary Beth BrinsonSo the next 12 to 24 months are going to be incredibly busy for Cyban . So some of the milestones that we'll be looking at over the next two years include we'll build out the United States team so we've hired one person there and we'll be looking to hire more to that team over the next two years . We'll finalize the full product , so the oxygen product and the intracranial pressure product , and then we'll execute a full market launch in the United States in about a year from now . We'll complete our IPO and ASX listing and we'll generate and report some revenues in the US more toward the end of the two-year mark as we go down the clinical adoption route and we'll gain regulatory approval for our stroke products . So very busy two years coming up .
Andrew MusgraveCertainly looks like it . So , Mary Beth , thanks for your time today . It's been great to get an overview of the company and we look forward to the next update in the coming months .
Mary Beth BrinsonThank you , Andrew , I really appreciate it .
Andrew MusgraveThat concludes this episode of ASX Briefs . Don't forget to subscribe and we look forward to catching you on our next episode .